Search Results

Your search filters:

solid tumor cancers

Showing 1-3 of about 3 articles.

RedHill Biopharma Ltd.

RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination

Notice of Allowance received for combination of RedHill’s novel orally-administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend IP...

November 04, 2020

Provectus Biopharmaceuticals Inc.

PV-10® Abstract Previously Accepted for Presentation at Terminated American Association for Cancer Research (AACR) Annual Meeting 2020

KNOXVILLE, TN, March 17, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today said that data from ongoing research into investigational lysosomal-targeting cancer immunotherapy PV-10 (rose bengal...

March 17, 2020

RedHill Biopharma Ltd.

RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares

TEL-AVIV, Israel, Feb. 13, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...

February 13, 2015

Showing 1-3 of about 3 articles.

Search Results

RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination

PV-10® Abstract Previously Accepted for Presentation at Terminated American Association for Cancer Research (AACR) Annual Meeting 2020

RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares

Newswire Distribution Network & Management

About Us